Portfolio

Axogen

Medical technology company dedicated to peripheral nerve repair


Developer and marketer of surgical solutions for peripheral nerve injuries

Headquartered in Alachua, Florida, AxoGen (Nasdaq: AXGN) has a portfolio of regenerative medicine products focused on peripheral nerve repair, including Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with an additional surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachment.

Surgeons using AxoGen products are moving away from the traditional nerve autograft harvest technique that requires an additional surgical site which may result in a loss of feeling where the autograft nerve was removed, potential pain at the donor site, or other known donor site morbidities to the use of Avance® Nerve Graft. Peripheral nerve repair with Avance® Nerve Graft does not require autograft nerve tissue harvest, thus avoiding the associated complications, comorbidities and expenses associated with the harvest procedure.

Related News

“The EW team is extremely knowledgeable, and their ability to identify great innovations and market opportunities, and help move those innovations forward by sharing expertise and assisting in business plan execution is remarkable. AxoGen is proud to have Essex as a partner in our continued growth.”

Karen Zaderej

CEO, AxoGen

Testimonials and endorsements reflect portfolio company management’s opinions and beliefs regarding the company and the investment. Such opinions and beliefs are subjective, do not represent a complete assessment of the company, the market or EW’s overall investment performance and cannot be independently verified. Such statements are being offered as references for purposes of demonstrating the benefits of working with the EW team and not for the purpose of soliciting investors. Portfolio company executives receive/received a salary and economics from the portfolio company. No executives were paid for their testimonial or endorsement. There is a conflict of interest in these unpaid testimonials and endorsements in that all speakers stand to benefit from EW’s success and they work/worked for an EW portfolio company.